Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:08 2024-07-17 am EDT			5-day change	1st Jan Change
99.06 ^CHF	+0.16%		+0.77%	+16.72%

Jul. 15	Brace for a flurry of speeches from Fed officials
Jul. 15	European companies cut jobs as economy sputters	RE

NOVARTIS AG : Goldman Sachs reiterates its Buy rating

January 24, 2023 at 02:32 am EST

Analyst Keyur Parekh from Goldman Sachs research considers the stock attractive and recommends it with a Buy rating. The target price differs slightly and is now set at CHF 105 versus CHF 106.

Latest news about Novartis AG

Brace for a flurry of speeches from Fed officials	Jul. 15
European companies cut jobs as economy sputters	Jul. 15	RE
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	Jul. 15	MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings	Jul. 12	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	Jul. 12	MT
Global markets live: KKR, Apple, Tesla, Oracle, McDonald's...	Jul. 12
Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected	Jul. 11	MT
Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected	Jul. 11	MT
Markets Powered by Alternating Current	Jul. 10
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	Jul. 10	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	Jul. 10	MT
European companies cut jobs as economy sputters	Jul. 09	RE
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief	Jul. 08	MT
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	Jul. 05	MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	Jul. 05	MT
NOVARTIS AG : Berenberg sticks Neutral	Jul. 03	ZD
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	Jul. 02	DJ
NOVARTIS AG : Receives a Buy rating from Jefferies	Jul. 02	ZD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	Jul. 02	ZD
Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector	Jul. 02	MT
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	Jul. 01	MT
New semester, new state of mind	Jul. 01
NOVARTIS AG : Gets a Buy rating from Goldman Sachs	Jul. 01	ZD
Foreign banks target Switzerland after UBS takeover of Credit Suisse	Jun. 24	RE
NOVARTIS AG : Barclays reaffirms its Sell rating	Jun. 24	ZD

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

01:00am - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm EDT

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.9 USD

Average target price

112.7 USD

Spread / Average Target

+0.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+16.72%	225B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B
SANOFI	+2.52%	125B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Goldman Sachs reiterates its Buy rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals